
This summary was created by AI, based on 4 opinions in the last 12 months.
Rocket Doctor AI (AIDR-CSE) leverages an innovative 'Shopify' model tailored for doctors, enabling them to maintain ongoing relationships with patients while utilizing a globally curated AI medical library for enhanced diagnoses. The company, which has achieved success in Canada, is now expanding into key U.S. markets, with some big insurance companies beginning to cover their services. While the market cap stands at a modest $75 million, the company has seen significant growth this year. Despite its promising technology and strategic partnerships, it currently operates with minimal revenue and negative cash flows. Experts note the need for tangible sales to assess future profitability, and while they see potential, they also recognize competitive pressures in the healthcare software sector.
Sort of a "Shopify" model for doctors. Lets a doctor see the same patients, compared to a Teladoc model when you never know who you're going to get. Allows doctors to specialize. Built-in medical library helps with diagnoses. Now ramping up from Canada to US, revenues should increase, and eventually will be EBITDA-positive.
AIDR is quite small at $75M market cap, after a 57% gain this year. It provides healthcare software solutions. Essentially, an AI doctor. But, currently it has minimal revenue, losses and negative cash flow. No analyst coverage. It does have some partnerships with insurance companies, with large numbers of members, so there is some potential here. But we need to see some sales in order to gauge what future profitability might be. There is competition in the space, certainly, as well. Insiders own 3%. While interesting, we would consider it too early here.
Unlock Premium - Try 5i Free
Uses AI with its global library of medicine that it custom-built over 8 years. Different from using ChatGPT, which looks everywhere trying to find an answer. They've run the program through the 12 patient scenarios given to med students, and it scored well enough to pass the exam.
Doctors like it because it helps with triage. Insurance companies like it because it cuts down costs. Has proven itself in Canada, and now going after the bigger market in the US -- starting to add the who's who of insurers such as UNH, Medicare, Medicaid, and HUM.
He wanted to use it as a Top Pick today, but it's just a bit too small of a market cap.
Rocket Doctor AI is a OTC stock, trading under the symbol AIDR-CSE on the undefined (undefined). It is usually referred to as or AIDR-CSE
In the last year, 4 stock analysts issued a Buy, Sell, or Hold rating on AIDR-CSE. 3 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is HOLD. Read the latest stock experts' ratings for Rocket Doctor AI.
Rocket Doctor AI was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Rocket Doctor AI.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Rocket Doctor AI.
Rocket Doctor AI is followed by 8 investors on Stockchase and is a trending stock that is worth watching.
Doctors can use a "Shopify" model to market their "business" and get repeat patients, while accessing a global medical library that's been created with AI. Rolled out in Canada, now in some big US states, and being covered by US insurance. Expects it to be EBITDA-positive by year's end.